Evogene (NASDAQ:EVGN, TASE: EVGN.TA) is a leading computational biology company aiming to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications.
Incorporating a deep understanding of biology and leveraging Big Data and Artificial Intelligence, Evogene established its unique technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products.
Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
Evogene leverages its technology through:
Partnerships — Evogene engages with leading companies for joint development of defined products utilizing Evogene’s unique solution. Later-stage development and commercialization of the product will typically be done by the partner.
Subsidiaries — Evogene has established independent entities focusing on defined commercial fields, holding an exclusive license to use Evogene’s unique solutions for product development. The subsidiary may develop and commercialize products independently or through strategic collaborations.